Page 12 - Coronavirus Vaccine

Data story: India logs 1,574 new Covid cases; death toll at 529,008

India has added 9,914 cases in the past 7 days

Data story: India logs 2,208 new Covid cases; death toll at 528,999

India has added 10,452 cases in the past 7 days

Evidence updated on blood clotting side effect of Covid-19 jab: Study

Scientists have uncovered more knowledge about the risk of developing a very rare blood clotting condition following vaccination against COVID-19, according to a study. Based on health data from five European countries and the US, the study shows an increased risk of the condition, called thrombosis with thrombocytopenia syndrome (TTS), after first-dose of the Oxford-Astrazeneca vaccine (same as Covishield in formulation). The study, published in The British Medical Journal (BMJ), also shows a trend towards an increased risk after the Janssen/Johnson & Johnson vaccine, compared with the Pfizer-BioNTech vaccine. The researchers stressed that the syndrome is very rare, but said the observed risks "should be considered when planning further immunisation campaigns and future vaccine development." TTS occurs when a person has blood clots (thrombosis) as well as low blood platelet counts (thrombocytopenia). According to the study, it is very rare and different from general clotting ...

India an important manufacturer of vaccines for world: White House

India is an important manufacturer of vaccines for the world, the White House said, acknowledging the crucial role the country played in supplying vaccines against COVID-19 globally. Because of its incredible manufacturing capacity, (India) has been a major exporter of vaccines, Dr Ashish Jha, White House Coronavirus Response Coordinator, told reporters at a news conference here on Tuesday. Responding to a question, Dr Jha said the QUAD partnership a strategic security dialogue between Australia, India, Japan and the US -- on coronavirus was important to the Joe Biden administration. I think India is an important manufacturer of vaccines for the world. I mean not just for India itself, this is a really important thing, he said at the White House news conference. Defending the Biden administration's decision to supply vaccines to the world, Dr Jha said the US will continue making them available for every low and several low- and middle-income countries. There are about 100 countri

Data story: India records 830 new Covid cases; zero deaths in last 24 hrs

India has added 11,392 cases in the past 7 days

Biden gets updated Covid-19 booster shot; urges people to get vaccinated

President Joe Biden rolled up his sleeve and got his updated COVID-19 booster shot on Tuesday, as he urged millions of people who have yet to be boosted to do so by Halloween, if possible, so they can gather safely with family and friends this holiday season. Get vaccinated, he said, noting that it's free. Not enough people are getting it. Biden also called on Congress to provide the billions of dollars the administration has requested to buy additional vaccines, tests and treatments. Some lawmakers have balked at the request for more than $20 billion in new coronavirus funding. Biden, who was flanked by his COVID-19 response team, declared that the fight against the spread of virus is global in nature and the funding we seek is critical to that effort. Over 20 million people, including nearly 1 in 5 older adults, have gotten the updated COVID-19 booster, the White House said. The vaccine has been reformulated to target the BA.4 and BA.5 subvariants of omicron, the most dominant ..

Japan rolls out Covid vaccination for children aged 6 months to 4 years

Japan began Covid-19 vaccination for children aged between six months and four years at a hospital in Tokyo

Data story: India records 862 new Covid-19 cases, lowest in 196 days

India has so far administered 2,195,665,598 vaccine doses

Latest news LIVE: Delhi's air quality second best on Diwali in seven years

From Diwali celebrations and Cyclone Sitrang to coronavirus cases and air pollution, catch all the latest developments from across the globe here

LIVE: Rishi Sunak says will run for Britain's PM again

'I want to fix our economy, unite our Party and deliver for our country,' tweets Sunak

Data story: India adds 2,112 new Covid cases; active tally at 24,043

India has added 14,321 cases in the past 7 days

Covid vaccine to cost $110-$130 per dose after US govt stops buying: Pfizer

Pfizer will charge USD 110 to USD 130 for a dose of its COVID-19 vaccine once the U.S. government stops buying the shots, but the drugmaker says it expects many people will continue receiving it for free. Pfizer executives said the commercial pricing for adult doses could start early next year, depending on when the government phases out its program of buying and distributing the shots. The drugmaker said it expects that people with private health insurance or coverage through public programs like Medicare or Medicaid will pay nothing. The Affordable Care Act requires insurers to cover many recommended vaccines without charging any out-of-pocket expenses. A spokesman said the company also has an income-based assistance program that helps eligible U.S. residents with no insurance get the shots. The price would make the two-dose vaccine more expensive for cash-paying customers than annual flu shots. Those can range in price from around $50 to $95, depending on the type, according to

Pfizer's Covid vaccine price hike seen giving revenue boost for yrs: Report

Outside the United States, Pfizer said it already has contracts with governments in many developed markets that extend through 2023 with prices that have already been set

Latest LIVE: Modi blames previous govts for 'neglecting' religious places

From PM Modi's Kedarnath, Badrinath visit to coronavirus cases, catch all the latest developments from across the globe here

Covishield production stopped in Dec 2021, says Serum Institute's CEO

CEO Adar Poonawalla said Serum Institute of India stopped producing Covishield vaccine from December 2021 and of the total stock available at that time, about 100 million doses had already expired

HPV vaccine prodn delayed due to Covid, to start supply in early 2023: SII

Serum Institute of India (SII) had to defer HPV vaccine production by two years due to the focus on COVID, and will start supplying small quantities of the dose to the Indian government in early 2023, a top official has said. Exports will have to wait till 2024, its chief executive Adar Poonawalla told reporters here on Thursday evening, adding that the company has to build a scale of manufacturing to over 150 million for that. HPV vaccines prevent certain kinds of cervical cancer. SII is the world's largest vaccine manufacturer which rushed with the production of multiple COVID vaccines at its facilities located here once the shot was approved for use. "The HPV facility was used by the COVID vaccines during the pandemic. That's why we had to delay the larger launch to next year," Poonawalla said, speaking on the sidelines of an event. "We will be making a very small quantity and launching with the Indian government in the first quarter of next year. Followed by a capacity for 70

Data story: India logs 2,119 new Covid cases; death toll at 528,953

India has so far administered 2,195,097,574 vaccine doses

Global rollout of 12 bn vaccine doses largest-ever but access an issue: WHO

World Health Organization (WHO) director-general Dr Tedros Adhanom Ghebreyesus on Thursday said global roll-out of more than 12 billion COVID-19 vaccine doses is the largest and fastest in human history. Addressing the annual general meeting of the Developing Countries Vaccine Manufacturers Network (DCVMN) virtually, he flagged the issue of inequities in access to COVID-19 vaccines. The three-day event is being co-hosted by the Pune-based Serum Institute of India (SII), the world's largest vaccine manufacturer by volume, said a statement. Global roll-out of more than 12 billion COVID-19 vaccine doses is the largest and fastest in history with an estimated 60 per cent doses produced by manufacturers in developing countries. Despite this achievement, stark inequities in access to COVID-19 vaccines remain," he said. "These inequities are due partly to the fact that globally vaccine production is too concentrated. To address this, the WHO and our partners have established the mRNA Tech

Developing nations' vaccine manufacturers bat for pandemic treaty

It's time to focus on routine immunisation: Mandaviya

SII stopped Covishield production in Dec 2021, says CEO Adar Poonawalla

Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla, on Thursday said the vaccine manufacturer stopped the production of Covishield vaccine starting December 2021, and of the total stock available at that time, around 100 million doses had already got expired. Speaking to reporters on the sidelines of the annual general meeting of Developing Countries Vaccine Manufacturers Network (DCVMN), he said booster vaccines have no demand as there is general lethargy among people and also because they are fed up with the pandemic. "Since December 2021, we stopped the production (of Covishield). We had a stock of a few hundred million doses at that time and of that, 100 million doses have already expired," said Poonawalla when asked about the update on the Covishield vaccine. He said the SII's vaccines are allowed to be mixed. "Now, Covovax should be allowed in two weeks. So I think they will and should probably have the policy to mix boosters. If WHO allowed it, then .